• 1
    Garcia-Carbonero R, Ryan DP, Chabner BA. Cytidine analogs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott-Raven Publishers, 1996; 26594.
  • 2
    Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 87590.
  • 3
    Ferrara F. Unanswered questions in acute myeloid leukemia. Lancet Oncol 2004; 5: 44350.
  • 4
    Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 115463.
  • 5
    Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc 2006; 81: 24760.
  • 6
    Fernandez HF, Rowe JM. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Curr Opin Hematol 2010; 17: 7984.
  • 7
    Wiley JS, Jones SP, Sawyer WH. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 1982; 69: 47989.
  • 8
    Inagaki A, Nakamura T, Wakisaka G. Studies on the mechanism of action of 1-beta-d-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res 1969; 29: 216976.
  • 9
    Graham FL, Whitmore GF. Studies in mouse L-cells on the incorporation of 1-β-d-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-d-arabinofuranosylcytosine 5'-triphosphate. Cancer Res 1970; 30: 263644.
  • 10
    Graham FL, Whitmore GF. The effect of 1-beta-d-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 1970; 30: 262735.
  • 11
    Kufe DW, Major PP, Egan EM et al. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980; 255: 89979000.
  • 12
    Yamauchi T, Ueda T, Nakamura T. A new sensitive method for determination of intracellular 1-β-d-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. Cancer Res 1996; 56: 18004.
  • 13
    Takemura H, Urasaki Y, Yoshida A et al. Simultaneous treatment with 1-beta-d-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 2001; 61: 1727.
  • 14
    Yamauchi T, Kawai Y, Ueda T. 1-β-d-Arabinofuranosylcytosine is cytotoxic in quiescent normal lymphocytes undergoing DNA excision repair. Cancer Sci (Jpn J Cancer Res) 2002; 93: 133441.
  • 15
    Yamauchi T, Ueda T. A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. Biochem Pharmacol 2005; 69: 1795803.
  • 16
    Yamamoto S, Yamauchi T, Kawai Y et al. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol 2007; 85: 10815.
  • 17
    Yamauchi T, Negoro E, Kishi S et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase / cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009; 77: 17806.
  • 18
    Negoro E, Yamauchi T, Urasaki Y et al. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol 2011; 38: 9119.
  • 19
    Prus KL, Averett DR, Zimmerman TP. Transport and metabolism of 9-beta-d-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res 1990; 50: 181721.
  • 20
    Rodriguez CO Jr, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res 1999; 59: 493743.
  • 21
    Rodriguez CO Jr, Mitchell BS, Ayres M et al. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002; 62: 31005.
  • 22
    Lotfi K, Månsson E, Peterson C et al. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-d-arabinofuranosylguanine cytotoxicity. Biochem Biophys Res Commun 2002; 293: 148996.
  • 23
    Enyedy IJ, Ling Y, Nacro K et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44: 431324.
  • 24
    Real PJ, Cao Y, Wang R et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004; 64: 794753.
  • 25
    Yamauchi T, Nishi R, Kitazumi K et al. A new high-performance liquid chromatography method determines low production of 9-beta-d-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. Oncol Rep 2010; 23: 499504.
  • 26
    Yoshio N, Kawai Y, Hori H et al. Resistance to 9-beta-d-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues. Int J Hematol 2005; 81: 40512.
  • 27
    Yamauchi T, Nowak BJ, Keating MJ et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 35809.
  • 28
    Yamauchi T, Kawai Y, Ueda T. Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay. Cancer Sci (Jpn J Cancer Res) 2002; 93: 56773.
  • 29
    Kasimir-Bauer S, Beelen D, Flasshove M et al. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 2002; 30: 13028.
  • 30
    Certo M, Moore VDG, Nishino M et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 35165.
  • 31
    Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-d-arabinofuranosylcytosine. Cancer Res 1984; 44: 502937.
  • 32
    Higashigawa M, Ido M, Nagao Y et al. Decreased DNA polymerase sensitivity to 1-beta-d-arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine. Leuk Res 1991; 15: 67581.
  • 33
    Schröder JK, Kirch C, Flasshove M et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 1996; 10: 191924.
  • 34
    Hubeek I, Stam RW, Peters GJ et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 138894.
  • 35
    Kawasaki H, Carrera CJ, Piro LD et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597601.
  • 36
    Galmarini CM, Graham K, Thomas X et al. Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 2001; 98: 19226.
  • 37
    Wang S, Vrana JA, Bartimole TM et al. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-d-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 1997; 52: 10009.
  • 38
    Schimmer AD, Estey EH, Borthakur G et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27: 47416.
  • 39
    Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol 2010; 4: 13341.
  • 40
    Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003; 102: 18428.
  • 41
    Kisor DF, Plunkett W, Kurtzberg J et al. Pharmacokinetics of nelarabine and 9-beta-d-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000; 18: 9951003.